Please enable JavaScript.
Coggle requires JavaScript to display documents.
dragons den, UKRI, candida auras, https://www.nature.com/articles/s43016…
dragons den
antimicrobial resistance
animal made antibodies
already used to target cancer cells alongside chemotheraphy for +20 years, help with reduction of lymphomas
-
serum injections were used in 1890s before antibiotics existed/became popular [used against measles, chickenpox, mumps, and poliomyelitis]
serum used in combination with antibiotics at start
therapy for illnesses, such as covid-19, requires injections of healthy serum from a person who has overcame the illness
-
low toxicities and high specificities, NO antibiotic resistance
can target exact pathogens but if pathgens stop displaying certain antigens antibody becomes obselete - new production = more time + cost
high costs of production, storage and administration of antibodies [prevention of RSV disease is estimated at £2,500], but non specific drugs may intotal cost more as patinets are required to stay in hospitals and receive further treatments
would require improvements in exact diagnosis of pathogens to work, so not available to use everywhere
-
-
-
-
waste water monitoring
Develop systems for monitoring and treating antibiotic residues in wastewater, as improper disposal of antibiotics can contribute to environmental AMR.
Food security
AMR in the food chain is a risk to exposed workers and consumers both locally and globally.
AMR in the food chain affects the achievement of Sustainable Development Goals related to poverty, hunger and promoting health and well-being.
The consequences of AMR in the food chain thus extend beyond reduced productivity and food safety to reach food insecurity, becoming a drain on national and global economies as well as worsening climate change.
Future implications:
Important with the growing population - a higher percentage of the produced food needs to be used - currently 1/3 is wasted.
-
-
-
animal welfare
using bacteria/yeast as an alternative for monocolonial antibodies, but plants with agrobacterium can also be used as an alternative producer
-
-
-
UKRI
FUNDS RESEARCH INTO:
understand the fundamental microbiology of organisms with known resistance prevalence in order to understand how resistance develops and is maintained, and to develop mitigation strategies
investigate the selection pressures for antimicrobial resistance and the dynamics of transmission at the genetic, organism and host level impacting on the design of measures to control resistance
-
develop novel diagnostics to enable rapid identification of antimicrobial-resistant organisms or presence of resistance genes.
Research to combat infectious disease in crops that is not aimed specifically at combatting AMR would normally come under the priority of sustainably enhancing agricultural production.
humans – including human physiology, cell biology, genetics and genomics if it’s relevant to understanding normal human function (but not if it’s focused on specific human diseases or abnormal conditions)
animal diseases – but not studies primarily involving animal models of human disease and human toxicology, including abnormal toxicological reactions and drug toxicity
wild species – when they are pests in an agricultural setting or pollinators of agricultural crops, or when they act as a suitable model and provide wider understanding of biological processes
-
-
This priority covers AMR in microbes associated with animal, plant and soils systems, plus relevant understanding of how such resistance could lead to the transfer of AMR to human pathogens or human commensal bacteria. It also includes generic research on how resistance develops in any microbial species, research on alternatives to antimicrobials and novel antimicrobials of relevance to all species.
Research will inform strategies for combatting the development of AMR in managed animals, crops and managed soil, with particular reference to the current situation in the UK. It will also underpin the development of novel alternatives of generic relevance to all species. Impacts on training and the future UK skills base should be considered.
It is anticipated that applicants proposing research on novel antimicrobials or alternatives to antimicrobials should demonstrate translational opportunities. For example, applicants could have an industrial partner involved with the application at some level or could indicate how the research might underpin future government policy.
-
-